We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
NMRA

Price
2.93
Stock movement up
+0.43 (17.20%)
Company name
Neumora Therapeutics, Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
474.50M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-75.27%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-10-30

DIVIDENDS

NMRA does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

FINANCIALS

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)-1.02

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash129.07M
Net receivables0.00
Total current assets177.08M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets177.83M
Accounts payable549.00K
Short/Current long term debt523.00K
Total current liabilities25.84M
Total liabilities45.67M
Shareholder's equity0.00
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.75
Daily high3.04
Daily low2.67
Daily Volume7.47M
All-time high19.76
1y analyst estimate8.50
Beta3.03
EPS (TTM)-
Dividend per share0.00
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
NMRAS&P500
Current price drop from All-time high-85.17%-1.10%
Highest price drop-96.89%-19.00%
Date of highest drop14 May 20258 Apr 2025
Avg drop from high-81.37%-2.76%
Avg time to new high-5 days
Max time to new high266 days89 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
NMRA (Neumora Therapeutics, Inc.) company logo
Marketcap
474.50M
Marketcap category
Small-cap
Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Employees
96
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...